The stock of Corvus Pharmaceuticals Inc (CRVS) has gone up by 20.94% for the week, with a 49.39% rise in the past month and a 274.52% rise in the past quarter. The volatility ratio for the week is 9.09%, and the volatility levels for the past 30 days are 8.40% for CRVS. The simple moving average for the past 20 days is 32.59% for CRVS’s stock, with a 185.85% simple moving average for the past 200 days.
Is It Worth Investing in Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Right Now?
Additionally, the 36-month beta value for CRVS is 1.14. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRVS is 50.12M and currently, short sellers hold a 4.29% ratio of that float. The average trading volume of CRVS on October 22, 2024 was 475.42K shares.
CRVS) stock’s latest price update
Corvus Pharmaceuticals Inc (NASDAQ: CRVS)’s stock price has soared by 7.50 in relation to previous closing price of 7.56. Nevertheless, the company has seen a gain of 20.94% in its stock price over the last five trading days. zacks.com reported 2024-09-11 that CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
Analysts’ Opinion of CRVS
Many brokerage firms have already submitted their reports for CRVS stocks, with Oppenheimer repeating the rating for CRVS by listing it as a “Outperform.” The predicted price for CRVS in the upcoming period, according to Oppenheimer is $7 based on the research report published on August 18, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see CRVS reach a price target of $8. The rating they have provided for CRVS stocks is “Buy” according to the report published on December 01st, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to CRVS, setting the target price at $10 in the report published on May 27th of the previous year.
CRVS Trading at 57.37% from the 50-Day Moving Average
After a stumble in the market that brought CRVS to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.27% of gains for the given period.
Volatility was left at 8.40%, however, over the last 30 days, the volatility rate increased by 9.09%, as shares surge +55.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +118.21% upper at present.
During the last 5 trading sessions, CRVS rose by +19.49%, which changed the moving average for the period of 200-days by +289.81% in comparison to the 20-day moving average, which settled at $6.12. In addition, Corvus Pharmaceuticals Inc saw 361.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRVS starting from Jones William Benton, who purchase 20,000 shares at the price of $1.73 back on May 06 ’24. After this action, Jones William Benton now owns 153,773 shares of Corvus Pharmaceuticals Inc, valued at $34,624 using the latest closing price.
MILLER RICHARD A MD, the President and CEO of Corvus Pharmaceuticals Inc, purchase 577,634 shares at $1.73 during a trade that took place back on May 06 ’24, which means that MILLER RICHARD A MD is holding 577,634 shares at $1,000,000 based on the most recent closing price.
Stock Fundamentals for CRVS
Current profitability levels for the company are sitting at:
- -95.12 for the present operating margin
- 0.59 for the gross margin
The net margin for Corvus Pharmaceuticals Inc stands at -91.93. The total capital return value is set at -0.46. Equity return is now at value -44.91, with -36.89 for asset returns.
Based on Corvus Pharmaceuticals Inc (CRVS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -15.17. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -15.05.
Currently, EBITDA for the company is -23.18 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 2060.11. The receivables turnover for the company is 2.02for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In conclusion, Corvus Pharmaceuticals Inc (CRVS) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
